Noninfectious pulmonary dysfunction (NIPD) is a common and often fatal complication associated with allogeneic hematopoietic stem cell transplantation (HSCT). An insertion/deletion polymorphism in the angiotensinconverting enzyme (ACE) gene has been extensively studied in relation to cardiovascular and renal disease, and lung fibrosis. In pulmonary fibrosis, D-allele frequency is significantly higher than in the control population. We hypothesized that a similar mechanism exists between post-HSCT NIPD and pulmonary fibrosis in the absence of HSCT. We retrospectively analyzed the incidence of NIPD and the ACE genotype polymorphism in 118 Japanese patients who underwent HSCT from HLAidentical sibling donors. NIPD occurred in 17 cases. Deletion/deletion genotype carriers were more common in the NIPD group than in the other 101 patients (41.2 vs 11.9%; hazard ratio, 5.19; 95% confidence interval, 1.67-16.21). There were no significant relationships between the clinical characteristics of patients and the development of NIPD. These findings suggest that the ACE genotype is associated with the development of NIPD following HSCT. This study is the first to report the relationship between genetic background and NIPD. Bone Marrow Transplantation (2005) 36, 617-620.
geneic hematopoietic stem cell transplantation; angiotensin converting enzyme polymorphism Hematopoietic stem cell transplantation (HSCT) has become the standard treatment for many hematologic disorders. Potentially lethal pulmonary complications, including infectious and noninfectious complications, occur in 30-60% of patients who receive allogeneic HSCT. 1 Noninfectious pulmonary dysfunction (NIPD) has a wide etiological spectrum. Early-onset noninfectious pulmonary complications include diffuse alveolar hemorrhage (DAH) and the idiopathic pneumonia syndrome (IPS). Late-onset noninfectious pulmonary complications include bronchiolitis obliterans (BO), bronchiolitis obliterans with organizing pneumonia (BOOP), diffuse alveolar damage (DAD), lymphocytic interstitial pneumonia (LIP), and nonclassifiable interstitial pneumonia (NCIP).
Risk factors for developing NIPD include previous infections, a pretransplant condition, a low performance status prior to transplantation, a high dose of total-body irradiation (TBI) (X12 Gy), and the presence of graftversus-host disease (GVHD). [1] [2] [3] [4] [5] Although NIPD is a significant clinical complication after allogeneic HSCT, progress in understanding its pathogenesis has been limited.
Angiotensin I-converting enzyme (ACE) is a dipeptidyl carboxypeptidase that plays an important role in blood pressure regulation and electrolyte balance by hydrolyzing angiotensin I into angiotensin II (A-II), a potent vasopressor and aldosterone-stimulating peptide. The ACE gene is located on chromosome 17q23, spans 21 kb, and contains 26 exons. A well-described polymorphism within intron 16 involves either the insertion or deletion of a 287-bp fragment. An individual's ACE genotype is thereby defined as insertion/insertion (I/I), insertion/deletion (I/D), or deletion/deletion (D/D). In most populations, the D/D genotype is associated with significantly higher levels of ACE and A-II compared to the I/I genotype, while individuals with the I/D genotype have intermediate levels of both enzymes. 6 A-II plays a well-described role in the control of systemic blood pressure and volume homeostasis. There is also evidence to suggest an important role for A-II in the fibrotic response to tissue injury. 7, 8 It has also been shown that an increased D-allele frequency is linked to pulmonary fibrosis. 9 There are two major sites of lung injury associated with post-HSCT interstitial pneumonitis including infiltration of the perivascular zones and alveolar septa by mononuclear cells and ongoing lymphocyte mediated injury to the large and small airways. 10 Accordingly, we hypothesized that subacute or chronic lung injury resulting from HSCT could indirectly induce pulmonary fibrosis as a result of its relationship to ACE and A-II levels. This study examined the association between the ACE genotype and the incidence of NIPD following HSCT.
Patients and methods

Study patients
A total of 118 recipients who had undergone HSCT from an HLA-A, B, and DR identical sibling at the Japanese Red Cross Nagoya First Hospital were genotyped. All patients underwent transplantation between December 1989 and March 2001. Patient characteristics are shown in Table 1 . GVHD prophylaxis was with cyclosporine-A and a short course of methotrexate. All procedures for dealing with the subjects were in agreement with the ethical standards of our institute.
Analysis of ACE polymorphism
Genomic DNA was purified from peripheral blood or bone marrow obtained before transplantation. The ACE genotype was determined by PCR amplification of intron 16, based on a previously described method.
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Definition of NIPD NIPD was diagnosed according to previously published criteria, such as evidence of widespread alveolar injury by multilobar infiltrate, manifest on chest X-ray or computed tomography, as well as clinical symptoms of pneumonia, hypoxemia, and evidence of abnormal respiratory physiology, including restrictive impairment in a pulmonary function test. 10,12. Bronchoalveolar lavage (BAL) and transbronchial lung biopsy were performed whenever possible.
To exclude lower respiratory tract infections, standard culture and staining methods for bacterial, viral, and protozoan pathogens were employed. Serologic tests were performed for herpes simplex virus, varicella zoster, cytomegalovirus (CMV), and Epstein-Barr virus. Weekly CMV pp65 antigenemia testing has been performed on patients since 1995.
Statistical analyses
Allele frequencies among the study patients and controls were tabulated and compared by w 2 test with values predicted on the assumption of a Hardy-Weinberg equilibrium in the sample. For each hazard ratio twotailed P-values and a 95% confidence interval was calculated. Differences in the onset of NIPD following stem cell transplantation between two groups were tested using a Mann-Whitney test.
Results
NIPD occurred in 17/118 patients (14.4%). The median time of onset was 100 days with a range of 60-380 days after stem cell transplant. The fatality rate among NIPD patients was 47.1%. Age, sex, disease, conditioning regimen, TBI dose, and grades of acute GVHD were not associated with the development of NIPD (Table 1) . Table 3 ). The mortality of patients with NIPD was not significantly associated with ACE polymorphism. 
ACE polymorphism and developing NIPD
ACE genotype and onset day of NIPD
An investigation of the relationship between ACE genotype and onset of NIPD revealed that NIPD patients with the D/D genotype tended to be diagnosed later than with the I/I or I/D patients (P ¼ 0.036) ( Table 4) .
Distribution of ACE polymorphism
Among all 118 patients, the frequency of the D/D, I/D, and I/I genotypes was virtually identical to those predicted by the Hardy-Weinberg equilibrium (13.3, 46.4, and 40.3%; w 2 ¼ 0.04, P ¼ 0.84). Moreover, the frequency of alleles and genotypes in all patients was not significantly different from those observed in 5014 Japanese subjects in a previous cohort study. 13 Similarly, there was no significant relationship between the underlying disease and the frequency of ACE genotypes.
Discussion
We found that ACE polymorphisms were associated with the development of NIPD following allogeneic HSCT. Patients with the D/D genotype produced higher levels of ACE and were more frequently diagnosed NIPD than patients with the I/D or I/I genotypes. Although we did not investigate the relationship between serum or BAL fluid ACE levels and the development of NIPD, the results of the present study are consistent with previous findings for the existence of a pulmonary renin-angiotensin system and the capacity for A-II generation within the lung. These findings include the demonstration of high A-II levels in the normal rat lung, 14 the expression of angiotensinogen and A-II type 1 receptors in lung tissue, 15 and the presence of elevated bronchoalveolar lavage fluid and/or serum ACE levels in several potentially fibrotic lung diseases. 16, 17 In experimental lung injury models induced by bleomycin, A-II stimulates lung fibroblast procollagen production via the AT1 receptor, and the autocrine production of TGF-b is a potent inducer of fibroblast procollagen synthesis. 18 In this lung injury model administration of an ACE inhibitor or an AT1 receptor antagonist has the capacity of reduce ACE activity, the concentration of A-II, TGF-b expression, and collagen deposition. It can be concluded from these findings that the pulmonary renin-angiotensin systems plays an important role in the development of lung tissue fibrosis.
NIPD following HSCT is thought to result from a diversity of lung insults, including the toxic effects of myeloablative conditioning, immunologic cell-mediated injury, and inflammatory cytokines. [19] [20] [21] The majority of patients have histopathologic patterns characteristic of interstitial pneumonia or diffuse alveolar damage. 10, 12 In idiopathic pulmonary fibrosis, wound healing ultimately leads to fibrosis and an associated loss of lung function. 22 The development of fibrotic lung injury is more commonly associated with subacute or chronic forms of pulmonary dysfunction following HSCT.
Consistent with a role for the renin-angiotensin system in fibrotic response to lung injury, the present study highlights the important role of the renin-angiotensin system particularly in the subacute or chronic fibrotic response to lung injury following HSCT. Based on this information, and the finding that ACE inhibitors can block experimental models of lung fibrosis, 23, 24 ACE inhibitors or AT1 receptor antagonists would provide a suitable option for treatment or prevention of NIPD following HSCT. In summary, this report shows that ACE gene polymorphisms are linked to the development of NIPD following allogeneic HSCT. Hazard ratio was NIPD vs non-NIPD. CI ¼ confidence interval.
Table 3
Hazard ratio for NIPD after HSCT in patients with the DD genotype
DD (%) ID+II (%)
Hazard ratio (95% CI) 
